According to the World Economic Forum, over 4.5 billion people lack access to essential healthcare services globally, and it is anticipated that by 2030, a shortage of 11 million health workers will impact the global healthcare landscape. Currently, the global healthcare industry is facing the crisis of skilled healthcare workers, skyrocketing bills, supply chain disruptions, and regulatory hurdles, which are a cry for help — for innovation, demanding a breakthrough. AI-powered genomics is answering that call, urging healthcare and life sciences leaders to recalibrate how diseases are diagnosed, treated, and managed by tailoring interventions to individual patients’ genetic, environmental, and lifestyle factors. Notably, AI-driven genomic analysis is expected to enhance precision medicine, particularly in cancer treatment, by identifying complex genetic variants associated with diseases. Moreover, personalised medicine is revolutionising healthcare by tailoring treatments to individual genetic profiles, utilising advancements to better predict disease vulnerability and treatment efficacy.

Genomics, the study of an individual’s complete genetic material, plays a critical role in understanding how genetic variations affect health and drug responses. It is anticipated that in the coming years, genomic data cost reduction and accessibility will provide crucial insights into how genetic variations affect health and drug responses. AI technologies, particularly machine learning, will be essential for analysing large-scale genomic information and identifying patterns, promising faster recoveries and fewer side effects.

Barriers in AI-Based Diagnostics and Genomic Data Sharing

There is no doubt that AI-based diagnostics and genomic data sharing are poised to revolutionise the healthcare sector. However, to fully leverage this potential, it is crucial to address several key challenges. Firstly, robust measures for data privacy and obtaining patient consent are needed to foster patients’ trust in these technologies. Additionally, focusing on increasing diversity within genomic datasets can help mitigate bias in AI algorithms, leading to more equitable outcomes. 

By addressing these barriers, the sector can streamline the integration of these innovations into clinical practice. Finally, prioritising affordability and accessibility, especially in low-resource settings, will ensure that the benefits of these advancements reach a broader population. Working collaboratively on these issues will enable us to harness the full capabilities of AI in healthcare.

Personalised medicine transforms how we approach, identify, and manage health issues. It is making a significant impact on both clinical research and patient care, and we can say that the influence is here to stay. However, certain market restraints need to be addressed, as the high cost associated with precision medicine is a major barrier to adopting AI in this field, particularly in underdeveloped regions. Advanced technologies like genomic sequencing and data processing are expensive to acquire and maintain, limiting their widespread adoption. Although the cost of whole-genome sequencing is decreasing, it’s still hundreds to thousands of dollars for each patient, hindering accessibility. The ordinary healthcare providers are struggling to justify the investment in AI solutions due to constraints such as resources and the hidden costs of system integration. The potential of precision medicine may remain untapped without substantial financial support.

Market Overview of AI in Precision Medicine 

As per the industry forecasts, the global AI in precision medicine market is anticipated to reach USD 26.66 billion by 2034, growing at a CAGR of 25.54%. This growth is driven by various factors, including technological advancements, investments, and favourable policies. AI has revolutionised the development of precision medicine for faster, more accurate results. Moreover, the government policies are supporting these changes by establishing guidelines for early cancer detection and AI integration in pharmaceuticals. Notably, increased investments from both public and private sectors, alongside public-private partnerships, are further accelerating market growth.

Currently, North America is the leader in AI in the precision market, with the U.S. personalised medicine sector valued at $170.14 billion in 2023, with a projected growth to expand to $387.40 billion by 2033. The region has foreseen significant advancements in precision medicine, backed by collaborations between research institutes and healthcare providers utilising AI for improved diagnostics and personalised treatments. Key industry players, including Johnson and Johnson, Google, IBM Watson, and NVIDIA, are at the forefront. This growth is supported by favourable regulatory frameworks and investments, including an additional $54 million from the US government for the Precision Medicine Initiative. The FDA has also approved 28 new personalised treatments in 2023, giving a major boost to the landscape. 

Meanwhile, initiatives like GenomeAsia100K are enhancing the medical advances for Asian populations, with China leading global efforts by investing $9.2 billion in its five-year plan. India’s recent AI Mission, backed by $1.25 billion in public-private partnerships, further strengthens the AI ecosystem. The European market is also expanding with robust government support, healthcare innovation funding, and increasing digital health adoption. 

Real-World Applications

Companies like Tempus, Foundation Medicine, and Colour Genomics are leading the way in providing integrated genomic services paired with AI-powered insights to enhance patient care. NVIDIA Corporation (US) launched NVIDIA NIM Agent Blueprints, a catalogue of pretrained, customizable AI workflows that equip enterprise developers with software for building and deploying generative AI applications for use cases, such as drug discovery, virtual screening, and precision medicine in 2024. Additionally, with the aim to accelerate drug discovery, enhance data analysis and enable the development of targeted therapies, Google (US) partnered with Recursion (US) in the previous year to bolster precision medicine through AI and cloud technology. This will be carried out by integrating Gemini models into the RecursionOS platform. Health systems, such as the Mayo Clinic and Mount Sinai, are developing precision medicine platforms that combine genomic data, AI, and Electronic Health Records (EHRS) to deliver more personalised treatments. Moreover, countries like the UK and Iceland are creating national genomic databases to improve public health planning and enable more tailored treatments, enhancing the overall effectiveness of healthcare.

The Future of Tailored Healthcare & Personalised Medicine

Personalised medicine is no longer a futuristic concept — it is shaping how diseases are predicted, prevented, and treated. With AI and genomics converging, the promise of truly individualised healthcare is closer than ever. By harnessing the genomic insights combined with advanced AI analysis, the healthcare sector will be better equipped to assess disease risks, customise treatments, and improve patient care.

However, the success rate of these innovative methods depends on overcoming barriers such as ensuring data privacy, addressing biases in AI systems, and promoting equitable access to healthcare solutions. 

Precision medicine is not just reshaping today’s healthcare—it is setting the foundation for the future of the healthcare industry. The industry is already witnessing strong momentum through strategic initiatives and investments, propelling the market forward, with the collaborative efforts of policymakers and industry leaders, such as NVIDIA, which is building the infrastructure for the next generation of drug discovery with its NIM Agent Blueprints, and Google’s collaboration with Recursion, leveraging powerful generative AI (Gemini models) to accelerate treatment development. As mentioned above, Tempus, Foundation Medicine, and Colour Genomics are delivering integrated AI-genomics platforms that enhance patient outcomes in real-world clinical settings. Meanwhile, leading healthcare institutions, such as the Mayo Clinic and Mount Sinai, are integrating genomic data, AI, and electronic health records to power next-generation clinical decision-making.

Also read: Eisai Pharmaceuticals to Launch GCC in Visakhapatnam, Accelerating Digital Healthcare Innovation

Regulatory backing, such as the FDA’s approval of 28 new personalised treatments in 2023, further validates the sector’s growing maturity and clinical relevance. From one-size-fits-all solutions to a greater emphasis on prevention, individuality, and precision tailored to unique characteristics, the healthcare landscape is undergoing a revolution. This evolution empowers society to harness the transformative potential of this cultural change, steering healthcare toward a future where precision medicine stands at the forefront, promoting a patient-centred, data-informed, and customised approach to health and wellness. Looking ahead, the trajectory is clear: the future of healthcare is moving decisively toward AI-driven, data-rich, precision medicine. 

Views expressed by: Ravi Shankar, Group Manager- Life Sciences & Chemistry, Ingenious e-Brain

Like 3

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect the official policy or views of any organisation. The content is intended for informational and educational purposes only and should not be construed as medical advice.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!